Phase 2 Solid Tumor trials recruiting now

All Solid Tumor trials, every phase

Other phases for Solid Tumor

Phase 2 Solid Tumor trials

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
  NCT06245330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
  NCT06008288 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
  NCT03829254 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
  NCT06475300 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 16 locations
• A Study of TRK-950 in Patients With Advanced Solid Tumors
  NCT05423262 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
  NCT04300556 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 116 locations
• A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT07003321 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
  NCT06669117 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
  NCT04513444 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
  NCT05381038 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 99 Years · Sex: All (male and female) · 1 location
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
  NCT07151040 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• RAPA-201 Therapy of Solid Tumors
  NCT05144698 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SMP-3124LP in Adults With Advanced Solid Tumors
  NCT06526819 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
  NCT06810544 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
  NCT04165772 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT06895031 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
  NCT04930432 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 87 locations
• Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
  NCT05784688 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Trop2-targeted immunoPET Imaging of Solid Tumors
  NCT06851663 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.